Sindhu Garg, MD
Nephrology · Aiken, SCNPI 1770623894
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.4% of the total across 242 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 12.5% — the pattern of someone who eats at a lot of different presentations.
Across 242 payments — averaging $22.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$685
- Otsuka America Pharmaceutical, Inc.$569
- Calliditas Therapeutics US Inc.$558
- Amgen$529
- Bayer$526
- Aurinia Pharma U.S., Inc.$371
- plus $2K from 20 others
What the payments were for
- Food & beverage$5,22595%
- Education$2515%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 35 | $685 |
| Otsuka America Pharmaceutical, Inc. | 21 | $569 |
| Calliditas Therapeutics US Inc. | 20 | $558 |
| Amgen(2 entities) | 27 | $529 |
| Bayer | 31 | $526 |
| Aurinia Pharma U.S., Inc. | 14 | $371 |
| Travere Therapeutics, Inc. | 13 | $339 |
| Vifor Pharma, Inc. | 14 | $247 |
| Ardelyx, Inc. | 7 | $226 |
| Akebia Therapeutics Inc | 7 | $189 |
| Fresenius USA Marketing, Inc. | 7 | $138 |
| OPKO Pharmaceuticals, LLC | 7 | $136 |
| Novo Nordisk | 5 | $125 |
| Mallinckrodt Hospital Products Inc. | 6 | $123 |
| Novartis | 4 | $110 |
| Organogenesis Inc. | 1 | $105 |
| Boehringer Ingelheim | 6 | $100 |
| Scpharmaceuticals Inc. | 5 | $85 |
| Cardiovascular Systems Inc. | 1 | $80 |
| GSK | 3 | $56 |
| Apellis Pharmaceuticals, Inc. | 2 | $56 |
| Mallinckrodt Enterprises LLC | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $32 |
| Sanofi | 1 | $21 |
| ANI Pharmaceuticals, Inc. | 1 | $21 |
| Baxter Healthcare | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,476 in reported general payments places this provider in the 80th percentile of 180 nephrology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 211 | $164,636 |
| JardianceEmpagliflozin | 96 | $62,708 |
| VelphoroSucroferric Oxyhydroxide | 18 | $41,933 |
| LokelmaSodium Zirconium Cyclosilicate | 24 | $24,292 |
| KerendiaFinerenone | 13 | $15,391 |
| JanuviaSitagliptin Phosphate | 17 | $15,241 |
| EntrestoSacubitril/Valsartan | 14 | $14,459 |
| EliquisApixaban | 11 | $6,597 |
| Sevelamer Carbonate | 37 | $4,725 |
| Midodrine Hcl | 31 | $3,919 |
| Chlorthalidone | 84 | $1,800 |
| Losartan Potassium | 181 | $1,278 |
| Allopurinol | 120 | $1,135 |
| Metolazone | 39 | $1,106 |
| Nifedipine ErNifedipine | 40 | $943 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $685 | $188,928235 claims |
| Boehringer IngelheimJardiance | $100 | $62,70896 claims |
| Fresenius USA Marketing, Inc.Velphoro | $138 | $41,93318 claims |
| BayerKerendia | $526 | $15,39113 claims |
| NovartisEntresto | $110 | $14,45914 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $21 | $48715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 180 nephrology providers in South Carolina.
Other nephrology in Aiken
- Douglas StahuraAiken$5K
- Jessica ColemanBeaufort$930K
- Moustafa MoustafaOrangeburg$616K
- Harold SzerlipCharleston$229K
- Barry GorlitskyGreenville$195K
- Blake ShustermanGreenville$66K
- Martin WebbBeaufort$66K
- Mohammed AlzubaidiSumter$54K
- Joshua LipschutzCharleston$44K
- Renee EllisColumbia$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.